Redeye comments on Cantargia's Q4 report, which contains progress with CAN10 and with nadunolimab in pancreatic cancer, now ready for a phase IIb trial.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Cantargia Q4 2023 - Progress with CAN10 and in PDA

© Modular Finance, source Nordic Press Releases